8-K: Elutia Amends Credit Agreement, Capitalizes Debt

Elutia Inc. has entered into a Fifth Amendment to its Credit Agreement, capitalizing accrued interest and fees into its senior secured term loan, increasing the principal balance to over $25 million.

Summary

• Elutia Inc. (formerly Aziyo Biologics, Inc.) entered into a Fifth Amendment to its Credit Agreement with SWK Funding LLC, effective August 15, 2025.
• The amendment capitalizes all accrued and unpaid interest due in August 2025, a $50,000 amendment fee agreed on June 30, 2025, and an additional $10,000 amendment fee into the unpaid principal balance of the Term Loan.
• This capitalization will result in an outstanding principal balance of the Term Loan of $25,089,029.71.
• The capitalized amount (August 2025 PIK Amount) will accrue interest from August 2025.
• The company previously converted 100% of the interest due on the May 2025 Payment Date to PIK (Payment-in-Kind) Interest at a rate of 4.5%.
• The original senior secured term loan was for an aggregate amount of $25.0 million, consisting of a $21.0 million Closing Date Term Loan (August 10, 2022) and a $4.0 million Subsequent Term Loan A (December 14, 2022).
• The company may request a third advance, a 'Subsequent Term Loan B,' of up to $5.0 million, subject to the Agent's and Lenders' sole discretion.
• The amendment includes financial covenants such as maintaining Minimum Consolidated Unencumbered Liquid Assets of at least $8,000,000 and Minimum Aggregate Revenue of at least $20,000,000 for the twelve-month period ending Q1 2024 and each fiscal quarter thereafter.

Sentiment

Score: 3

Explanation: The capitalization of interest and fees into the principal balance, coupled with the ongoing litigation and the explicit need for a future capital raise, indicates significant financial distress and liquidity challenges. While the amendment provides short-term relief, it points to a precarious financial position and potential future dilution for shareholders.

Positives

• The amendment provides Elutia with immediate cash flow relief by allowing the capitalization of accrued interest and certain fees into the principal balance of the term loan.
• The lenders' agreement to this amendment indicates continued support for the company, providing financial flexibility during a challenging period.
• The credit agreement includes provisions for a potential decrease in the Applicable Margin (interest rate) if the company achieves a 'Subsequent Capital Raise' of at least $10,000,000 or reaches a certain level of 'Consolidated Unencumbered Liquid Assets', incentivizing financial improvement.

Negatives

• The capitalization of accrued interest and fees into the principal balance increases the overall debt burden, indicating potential liquidity challenges and an inability to make cash payments.
• Elutia incurred two amendment fees totaling $60,000 ($50,000 agreed on June 30, 2025, and $10,000 under the current amendment) to modify the credit agreement.
• The ability to elect Payment-in-Kind (PIK) interest, including 100% for the May 2025 payment, suggests a need to conserve cash and points to ongoing financial strain.
• The company is required to file a Form S-3 Registration Statement for a potential capital raise of up to $20,000,000, partly to address the 'FiberCel Net Liability Amount,' indicating a future need for significant external funding.

Risks

• Ongoing 'FiberCel Litigation' poses a financial risk, potentially requiring a capital raise (Subordinated Debt or Equity Interests) to cover the 'FiberCel Net Liability Amount'.
• Failure to meet financial covenants, such as maintaining Minimum Consolidated Unencumbered Liquid Assets of $8,000,000 or Minimum Aggregate Revenue of $20,000,000, could trigger an Event of Default.
• The company's reliance on capitalizing interest and fees suggests underlying cash flow and liquidity issues, which could worsen if business performance does not improve.
• The discretion of the Agent and Lenders to approve a 'Subsequent Term Loan B' of up to $5,000,000 means this potential funding is not guaranteed.
• The terms of the loan include various events of default, including non-payment, default under other debt, bankruptcy, non-compliance with loan documents, false representations, and material adverse effects on the company's financial condition or collateral.

Future Outlook

Elutia Inc. is planning a potential capital raise of up to $20 million through Subordinated Debt or Equity Interests, partly to address the 'FiberCel Net Liability Amount' and for general business purposes. The company aims to reduce its interest rate margin if it successfully completes a 'Subsequent Capital Raise' of at least $10 million or significantly increases its 'Consolidated Unencumbered Liquid Assets'.

Management Comments

• Matthew Ferguson, Chief Financial Officer, signed the report on behalf of Elutia Inc.

Industry Context

This amendment reflects a common strategy for companies in the healthcare and biologics sector, particularly those facing litigation or needing to manage cash flow, to restructure debt. The capitalization of interest and fees, while providing immediate liquidity relief, can signal underlying financial pressures. The mention of 'FiberCel Litigation' highlights specific product-related legal challenges common in the medical device and biologics industry, which often necessitate significant financial provisions or capital raises.

Comparison to Industry Standards

• The capitalization of interest and fees into the principal balance is generally not a standard practice for financially robust companies. It is more commonly seen in companies experiencing cash flow constraints or seeking to defer immediate cash outflows, which could be considered worse than industry standards for healthy, growing firms.
• The requirement for a potential future capital raise of up to $20 million, partly to address litigation liabilities, suggests a financial position that may be weaker than well-capitalized industry peers who can absorb such costs internally or through less dilutive means.
• The existence of specific financial covenants (Minimum Consolidated Unencumbered Liquid Assets, Minimum Aggregate Revenue) and the ability to reduce interest rates based on future capital raises or liquidity improvements are typical for debt agreements with companies in a more challenging financial position, aiming to incentivize financial stabilization.

Legal Proceedings

• The company is involved in 'FiberCel Litigation', which refers to pending, threatened, or future claims related to or arising from the June 2021 recall of its FiberCel product.

Related Party Transactions

• The filing references Schedule 7.7 for existing affiliated agreements, but no new specific related party transactions are detailed in the amendment itself beyond standard compensation and employment arrangements.

Stakeholder Impact

• Shareholders face potential dilution from future equity raises and increased debt burden, which could negatively impact future profitability and share value.
• Creditors (Lenders) are deferring cash interest and fee payments, which are capitalized into the principal, increasing the total amount owed but indicating a higher risk profile for the loan.
• Employees, customers, and suppliers are not directly impacted by the amendment, but the company's financial distress could indirectly affect business operations and relationships.

Next Steps

• Elutia Inc. is to file a Form S-3 Registration Statement with the SEC for a potential capital raise of up to $20,000,000.
• The company must issue Subordinated Debt or Equity Interests within 90 days of the final determination of the 'FiberCel Net Liability Amount'.
• Elutia Inc. is required to provide the Agent with ongoing material updates regarding the 'FiberCel Litigation'.

Key Dates

Recommendation

The capitalization of accrued interest and fees into the principal balance of the term loan is a strong indicator of significant financial distress and liquidity issues. This action defers immediate cash outflows but increases the overall debt burden. Coupled with the ongoing 'FiberCel Litigation' and the explicit need for a substantial future capital raise, the company faces considerable financial headwinds. These factors suggest a high-risk investment profile with potential for further share price decline and dilution, making a 'sell' recommendation appropriate for a seasoned investor.

Keywords

Elutia Inc., SWK Funding LLC, Credit Agreement, Term Loan, Debt Capitalization, PIK Interest, SEC Filing, 8-K, Financial Covenants, Liquidity, Capital Raise, FiberCel Litigation, Corporate Finance, Biologics